Prospective Randomized Study of Accelerated Radiation Therapy (PRART) (NCT04175210)
🩺 Plain-English Summary (8th-Grade Level)
Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experimental).
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (5 items).
Location: New York Presbyterian Hospital at Lower Manhattan Cancer Center — New York, New York
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Previous radiation therapy to the ipsilateral breast.
- 90 days from last surgery, unless s/p adjuvant chemotherapy
- 60 days from last chemotherapy
- Male breast cancer
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (3 Sites)
- New York Presbyterian Hospital at Lower Manhattan Cancer Center — New York, New York
- Brooklyn Methodist Hospital - NewYork Presbyterian — New York, New York
- New York Presbyterian Hospital - Queens — New York, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.